FDA 483 - Biomedical Research Foundation of Northwest Louisiana - February 20, 2026

The FDA inspected Biomedical Research Foundation of Northwest Louisiana, a PET drug manufacturer in Shreveport, LA, and identified significant deficiencies. The firm was cited for inadequate facilities and environmental controls, insufficient production and process controls, and a lack of proper written procedures for material handling and quality assurance. Additionally, the inspection revealed a failure to adequately investigate out-of-specification results, indicating a high risk of product contamination and compromised drug quality.